KRAS G12C MUTANT SOLID TUMORS
Clinical trials for KRAS G12C MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for KRAS G12C MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack targets hard-to-treat KRAS G12C cancers
Disease control OngoingThis study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not …
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC